GB2197720A - Immobilisation of polynucleotides - Google Patents

Immobilisation of polynucleotides Download PDF

Info

Publication number
GB2197720A
GB2197720A GB08627703A GB8627703A GB2197720A GB 2197720 A GB2197720 A GB 2197720A GB 08627703 A GB08627703 A GB 08627703A GB 8627703 A GB8627703 A GB 8627703A GB 2197720 A GB2197720 A GB 2197720A
Authority
GB
United Kingdom
Prior art keywords
polynucleotide
dna
wells
plates
plate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08627703A
Other versions
GB8627703D0 (en
Inventor
Stephen Pedley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Priority to GB08627703A priority Critical patent/GB2197720A/en
Publication of GB8627703D0 publication Critical patent/GB8627703D0/en
Publication of GB2197720A publication Critical patent/GB2197720A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The problem of immobilising a polynucleotide on a welled plastics support, such as a 96-well microtitre plate, has been overcome by the finding that a branched polyethylenimine bonds to the plate and can be bonded to polynucleotides, such as DNA, RNA or oligonucleotides, by a cross-linking agent such as glutaraldehyde. A polynucleotide present in an analyte can be assayed by binding it to the plate, probing it with a labelled complementary polynucleotide under hybridisation conditions, and detecting the presence or amount of the label. The plate is made preferably from polyvinyl chloride or polystyrene.

Description

EMMOBILISATION OF POLYNUCLEOTIDES Background of the invention 1. Field of the invention This invention relates to the immobilisation of polynucleotides such as nucleic acids on rigid plastics surfaces such as welled plastics plates, especially those usually referred to as microtitre plates, or plastics tubes.
2. Description of prior art It is known to immobilise polynucleotides, especially DNA, on nitrocellulose and diazo papers and on nylon-based membranes, and to carry out hybridisations using such immobilised DNA. It would be an advantage to be able to immobilise polynucleotides on welled plastics plates such as microtitre plates, conventionally having 8 rows of 12 wells, so that assays depending on hybridisation of the polynucleotide to a complementary polynucleotide in an analyte can readily be carried out in the wells. However, a satisfactory method of immobilising DNA on the plastics material of the plates has not so far been devised.
There is a body of literature relating to the immunoassay of native DNA, for example in a patient suffering from systemic lupus erythematosus. In such immunoassays the wells of a microtitre plate are coated with a basic protein or polypeptide, especially methylated BSA, poly-L-lysine or protamine (a protein containing a high proportion of residues of basic amino acids and obtained from fish sperm). "Antigen DNA", such as calf thymus DNA is then added, the attraction between protonated amino groups of the protein or polypeptide and phosphate groups of the DNA apparently being responsible for binding the DNA to the protein or polypeptide.
The "antigen DNA" will bind to anti-DNA antibodies in the analyte and bound anti-DNA is detected, typically in the usual manner of a sandwich ELISA by adding anti-human immunoglobulin conjugated to an enzyme label, washing and assaying the bound label. See, for example M. Kavai et al., J. Immunological Methods 48, 169-175 (1982), R. Rubin et al., ibid. 359-366 (1983), especially the discussion on pages 364 and 365, and B. Leipold and W. Perry ibid. 66, 227-234 (1984). It has been claimed that single-stranded DNA can be absorbed directly on to polystyrene tubes, for use in immunoassay, see E. Engvall, The Lancet ii, 1410 (1976).
While the above methods of binding DNA to plastics microtitre plates or tubes have been used in immunoassay, it has remained a problem how to achieve sufficiently strong binding of DNA to such plastics supports to withstand the severe conditions of hybridisation. Hybridisations are typically carried out in a buffer containing significant loadings of salts, e.g. 0.5 to 1.0 M sodium chloride and frequently a washing at a temperature well above 37 C is required to remove any second strand DNA not stringently bound (and therefore not wholly complementary) to the first strand DNA.
Y. Nagata et al., FEBS Letters 183, 379-382 (1985) have described a method of binding DNA to microtitre plates ("Microfluor", Dynatech), for use in a hybridisation assay, in which denatured DNA in a buffer containing magnesium or calcium ions was incubated overnight in the plate wells, the solution removed and the DNA fixed by UV irradiation. The paper shows only picogram amounts of DNA bound to the wells.
Further prior art is described after the Summary of the invention, without which its context would not be clear.
Summary of the invention It has now been found that polyethylenimine (PEI), a branched polymer having free primary or cross-linkable secondary amino and also a proportion of cationic protonated amino groups, will bond well to most plastics surfaces and also, with the aid of an appropriate cross-linking agent, such as glutaraldehyde to a polynucleotide.
In an important aspect, the present invention provides a rigid plastics support, especially a welled plastics plate, having bonded thereto a polyethylenimine. Such plates can be stored for considerable periods.
The invention further provides a method of immobilising a polynucleotide on a plastics support, especially in wells of a welled plastics plate, which comprises incubating a support as defined above (having the PEI bound thereto) with the polynucleotide and with a cross-linking agent effective to link the primary amino groups of the PEI to reactive groups on the polynucleotide.
The invention enables assays for polynucleotides to be carried out. Thus, a method of assay of a polynucleotide in an analyte may comprise: (1) if the polynucleotide is not already in a single-stranded form, free of secondary structure or duplex which would interfere with hybridisation, denaturing it to remove said secondary structure or duplex, (2) immobilising the polynucleotide on the support, preferably in wells of a welled plastics plate, by the immobilisation method defined above, (3) probing the immobilised polynucleotide with a labelled complementary polynucleotide under hybridisation conditions, and (4) detecting the presence or amount of label bound to the support, i.e. to the wells where a welled plastics plate is used.
Additional description of prior art Polyethylenimines are polymers obtainable by the ring-opening cationic polymerisation of ethylenimine of formula (1).
and are highly branched, and believed to contain primary, secondary, and tertiary amine groups in the ratio of approximately 1:2:1.
There is experimental evidence that branching sites are separated mainly by secondary amine groups, with about one branch for every 3 to 3.5 nitrogen atoms within a linear chain as depicted in the illustrative, non-limiting formula (2) below
They have been reviewed by D. Horn of BASF in "IUPAC International Symposium on Polymeric Amines and Ammonium Salts, September 24-26, 1979, Ghent, Belgium", pages 333-355. This review includes on pages 341-345 a discussion of adsorption of PEI onto cellulose and silica.
M. Renz and C. Kurz, Nucleic Acids Research 12, 3435-3444 (1984) describe a method of linking a protein to DNA, whereby the protein serves as a label for the DNA. Preferably the protein is an enzyme which is readily detectable by reaction with an appropriate substrate. The linking reaction involves covalently bonding benzoquinone to horseradish peroxidase or alkaline phosphatase and then cross-linking the enzyme to DNA by use of PEI and glutaraldehyde.
The DNA thus labelled is useful as a probe. The authors suggest that the PEI reacts with the benzoquinone to form a positively charged tail on the enzyme. The DNA interacts with the tail by ionic binding, presumably (although the paper does not say so) through negatively charged phosphate groups on the DNA interacting with protonated amino groups of the PEI. The authors say that this ionic binding is essential for a successful cross-linking reaction (with the glutaraldehyde) leading to covalent bonds.
W.E. Meyers et al., J. Amer. Chem. Soc. 99, 6141 and 6142 (1977) have prepared a catalyst which they describe as a "polyethylenimine ghost". PEI is adsorbed onto porous alumina beads and then crosslinked with glutaraldehyde. The imine linkages are reduced with sodium borohydride. The alumina support is then removed by leaching with 1 N hydrochloric acid. The PEI ghosts were reacted with a protected histidine derivative to introduce histidyl groups. The imidazole function of the histidyl groups acted as a catalyst for the hydrolysis of k-nitrotrifluoroacetanilide.
What is novel and inventive in the present invention over the above prior art is the discovery that PEI bonds well to ordinary plastics surfaces and especially welled plastics plates and that such bonding is sufficiently stable to allow hybridisations to be carried out in the plates between the bound polynucleotide and its complementary partner.
Description of the preferred embodiments The PEI used can be any possessing primary or secondary amino groups and cationic protonated amino groups, at a reasonably high molecular density. This will ordinarily require that the main chain or backbone of the polymer contains secondary or tertiary amino groups, and that there should be branching. Sufficient primary and/or secondary amino groups are required for good reaction with the cross-linking agent, e.g. as is well known in the immobilisation of proteins. Secondary amino groups can usually be cross-linked except when they are sterically hindered or the amine-cross-linking agent reaction is difficult. Sufficient protonated amino groups are required for attraction to DNA phosphate groups at many places in the molecule.These can be primary, secondary or tertiary amino groups, but bulky N-substituents which might hinder ease of approach to the DNA by the PEI are best avoided. With these principles in mind, it is suggested that at least 25%, preferably at least 50%, of the amino groups should be protonated and at least 5%, preferably at least 15% should be unprotonated primary amino groups.
Polyethylenimines of any of the kinds described by D. Horn, supra, and complying with the basic requirements of having primary or cross-linkable secondary amino and protonated amino groups are preferred. One particularly suitable PEI is "Polymin G-35" of BASF, the properties of which are described in a technical bulletin dated January 1981 available from BASF. It has a refractive index at 20 C of 1.44s-1.455, a viscosity at 20 (Höppler) of 400-500 mPa.s, density of 1.06-1.12 g/cm3 and a pH in 1% aqueous solution of 9.5-11.5.
From experiments it would appear that 50 micrograms of PEI is sufficient to coat each well. Higher levels, up to 500 micrograms per well, do not increase significantly the binding capacity of the plates. Concentrations of PEI below 50 micrograms per well reduce the binding capacity of the plates.
The welled plates include any of those currently available, which are broadly describable as of polyvinyl chloride or polystyrene. Other plastics will be found usable, including particularly copolymers of vinyl chloride or styrene with other monomers and acrylic polymers. Preferably microtitre plates having 96-wells are employed, these being stock equipment in most biological and clinical laboratories.
It is conceived that the invention will be operable in relation to any rigid plastics surface, although polystyrene and PVC are preferred. Interestingly, the PEI binds even to plates which are given a small positive electrical charge by the manufacturer.
The PEI-coated plates can be stored, e.g. for two months at 40C, without loss of activity.
The PEI has to be linked durably to the polynucleotide which will require covalent bonding of some kind. It is believed that glutaraldehyde functions by bridging free primary or secondary amino groups on the PEl to free amino groups on the DNA bases, especially to amino groups in adenine, guanine and cytosine residues. Other NH2-NH2 linking groups or spacer arms known in protein chemistry can be substituted, for example polyacrylic acid. Other kinds of cross-linkage to DNA are not excluded as a matter of principle. It appears that the glutaraldehyde also assists bonding of the PEI to the plastics surface.
The invention is expected to find most applicability in assays. The polynucleotide in the sample, herein referred to "analyte polynucleotide", can be any RNA or DNA or derivative thereof and can be of any length, within reason. It is normally wise to denature the polynucleotide to remove any undesired secondary structure or double-stranded material, thereby to minimise possible interference with hybridisation. Denaturing inevitably breaks down the length of the nucleic acid, typically to lengths of less than 500 nucleotides long. In certain circumstances, it might be wished to immobilise a single-stranded oligonucleotide, for example one synthesised chemically, as short as say 5 nucleotides in length, for example as a primer to enable a complementary DNA to be made in the wells of the plate by priming a nucleic acid in a sample.
The wells of most plates will bind a maximum of from 2 to 5 micrograms of polynucleotide depending on the amount of PEI coated, the length of the polynucleotide and the size of the well.
Such large amounts of polynucleotide are not ordinarily required, however. The invention enables as little as 30 picograms of a particular polynucleotide in a mixture of polynucleotides to be detected, using biotinylated polynucleotide probes and enzymelabelled streptavidin. When a radiolabelled polynucleotide probe is used the amount of bound radioactivity can be measured by cutting the wells from the plate. The concentration of polynucleotide can be adjusted appropriately to ensure that a suitable amount, normally between about 20 picograms and 5 micrograms, preferably between 1 nanogram and 1 microgram, is bound to the well.
The probe polynucleotide is complementary to the analyte polynucleotide in that it will hybridise to it under reasonable conditions. The probe can be labelled in any convenient way, e.g. with a radiolabel such as alpha 32P, bipotinylated, or enzyme-labelled by other means including the method of M. Renz et al., supra. The label can be "read out" by any appropriate method such as autoradiography, enzyme-labelled avidin or streptavidin (making use of the biotin-avidin or biotin-streptavidin interaction) or the use of an enzyme in the Renz et al. method. Another method of enzyme labelling a probe is described in PCT Application WO 84/03520 (Alan Malcolm et al.). The enzyme can be detected by adding an appropriate colour-forming, fluorescent or luminescent substrate and reading the colour, fluorescence or luminescence, as is well known in the immunoassay art.
The invention provides a valuable advance in the assay field by enabling assays for DNA to be carried out in multiwell plates.
Other uses, such as in DNA sequencing, will suggest themselves to the expert in the art.
The following Examples illustrate the invention.
EXAMPLE 1 In this Example, polyvinyl chloride 96-well microtitre plates sold under the Trade Mark "FALCON" (Becton Dickinson Labware, California, USA) were coated with polyethylenimine (PEI). PEI "G-35" (BASF) was diluted to 10 mg/ml in 5 mM sodium phosphate buffer, pH 6.8. 100 microlitres of the diluted PEI were added to each well and the plates were incubated overnight at 4 0C. The plates were then washed thoroughly with 5 mM sodium phosphate buffer, pH 6.8, and dried at room temperature and under reduced pressure.
The dried plates were stored at 40C.
The nucleic acid to be assayed (the "analyte" nucleic acid) was cloned double-stranded complementary DNA to foot and mouth disease virus RNA of type A10 strain 61 (see UK Patent 2084583B).
The nucleic acid was diluted with the above-mentioned phosphate buffer in order to avoid coating the plate with excess. The binding capacity of the wells is about 5 micrograms of nucleic acid.
A typically suitable concentration is one which provides 30 picograms to 5 micrograms per well. The DNA was then denatured and made single-stranded by immersing it in boiling water for 5 to 10 minutes and cooling it rapidly in an ice bath. 50 microlitres of the ss DNA solution was added to each well. 6 microlitres of 5 g/100 ml solution of glutaraldehyde in the abovementioned phosphate buffer were added to each well. The plates were incubated at 37 C for 30 minutes with constant shaking and then washed thoroughly with the same phosphate buffer. The plates having DNA immobilised thereon were used for hybridisation.
For hybridisation, the same cloned FMDV and DNA was used. It was made single-stranded as described above and then nick-translated to replace deoxythymidine residues by biotinylated deoxyuracil residues, using a nick-translation kit supplied by BRL, Cambridge, UK. This biotin labelling method is that pioneered by D.C. Ward of Yale University and described in European Patent Specification 63879A.
Biotin-labelled probe nucleic acid having a length of 50-200 nucleotides was stored at a concentration of approximately 40 micrograms/ml in 5 mM phosphate buffer pH 6.8 at 200C. Immediately prior to hybridisation the probe nucleic acid was denatured by boiling (2 to 3 minutes) and diluted to the final concentration of between 100 and 100 ng/ml in hybridisation buffer. The composition of the hybridisation buffer was as follows: 50% Deionised formamide (BDH Chemicals, deionised with Amberlite resin, also from BDH Chemicals); 5 X SSC; 50 mM Sodium phosphate buffer pH 6.8; 0.04% w/v each of bovine serum albumin, Ficoll (type 70, Sigma Chemical Company), Polyvinylpyrrolidone (BDH Chemicals); 500 micrograms Ribonucleic acid from Torula Yeast Type VI, Sigma Chemical Company).
50 microlitres of hybridisation buffer was added to each well of the plate. Hybridisation was carried out overnight at 370C with continuous shaking.
Hybridisation buffer was removed from the wells and the plate washed with several changes (4 or 5 normally) of 2 X SSC. Each of these washes was only short, being used principally to remove the hybridisation buffer and probe nucleic acid which remained in solution. The plate was then washed twice (5 minutes each) with 2 X SSC at 37 C. Finally the plate was washed 3 times (10 minutes each) in 0.1 X SSC at 50 C.
The washing conditions described above can be adjusted to suit the level of nucleic acid homology required.
The biotin-labelled nucleic acid was detected by the use of a streptavidin-biotinylated horseradish peroxidase conjugate (Amersham International PLC). The plate was washed once with Phosphate Buffered Saline (PBS) and 50 microlitres of a 1 in 500 dilution of the horseradish peroxidase conjugate, in PBS containing 2% w/v "Marvel" (Cadbury's), added to each well. ("Marvel" acts very efficiently as a general blocking agent, and is considerably cheaper than the more commonly used bovine serum albumin). The plate was incubated at 37 0C for 15 minutes with continuous shaking.
Excess horseradish peroxidase conjugate was removed by thoroughly washing the plate with PBS followed by two brief washes with PBS containing 0.01% v/v Triton-X-100 and finally several more washes with PBS.
Horseradish peroxidase was detected using a 0.04% w/v solution of o-phenylenediamine (OPD) in citrate buffer (pH 6.6) containing 0.015% v/v H202. 50 microlitres of the OPD solution was added to each well and the plate incubated at room temperature for approximately 15 minutes. The reaction was stopped by addition of 50 microlitres of 1.25 N H2S04 and the adsorbance at 492 nm measured on a Flow Titertek microtitre plate recorder.
EXAMPLE 2 Example 1 was repeated using as the analyte nucleic acid single-stranded RNA from FMDV type A10 strain 61 and cloned cDNA to make the probe.
The procedure of Examples 1 and 2 was carried out in a single 96-well plate using various dilutions of the analyte nucleic acid, from 5 to 250 picograms and a blank (no analyte nucleic acid) in the 12 wells of row A (ds DNA) and row C (viral RNA).
Controls (no coating of the wells) occupied rows E and G. Each experiment was carried out in duplicate, in 12 wells per row, row B being a repeat of row A, row D a repeat of row C etc. The results of Table 1, show a detection limit of 30 picograms for the BNA. (This difference may be explained by making allowance for the length of nucleic acid sequence in the probe that can hybridise to the analyte nucleic acid. Both the cloned insert and the plasmid vector are available for hybridisation to the anlyte DNA whereas only the insert will hybridise to the bound RNA.) The control wells and the blanks all gave similar results indicating no hybridisation.
EXAMPLE 3 Example 1 was repeated using as the analyte nucleic acid the ds viral DNA of the sheep pox virus capripox. Cloned cDNA was used to make the probe.
TABLE 1 Figures represent the mean optical density measured at 492 nm, of duplicate wells.
Well number and amount of analyte DNA per well 1 2 3 4 5 6 7 8 9 10 11 12 250 pg 200 pg 150 pg 100 pg 60 pg 50 g 40 pg 30 pg 20 pg 10 pg 5 pg Blank A-B 0.611 0.721 0.586 0.800 0.713 0.690 0.515 0.370 0.279 0.271 0.272 0.280 C-D 0.572 0.560 0.463 0.365 0.331 0.350 0.289 0.260 0.245 0.241 0.239 0.256 E-F 0.268 0.267 0.267 0.267 0.277 0.282 0.281 0.279 0.274 0.271 0.270 0.274 G-H 0.243 0.231 0.243 0.239 0.244 0.250 0.248 0.248 0.242 0.237 0.238 0.255 Key Row A-B : Cloned ds DNA of FMDV RNA type A10 Strain 61.
Row C-D : Virus RNA of FMDV type A10 strain 61.
Row E-F : As for A-B but without PEI coating.
Row G-H : As for C-D but without PEI coating.
EXAMPLE 4 Example 1 was repeated using as the analyte nucleic acid double-stranded RNA of the blue-tongue virus, one of the reoviridae family. For the probe, cDNA was made by random priming and reverse transcriptase.
EXAMPLE 5 Example 3 was repeated using polystyrene 96-well microtitre plates sold under the Trade Mark "NUNC" (Intermed, Roskilde, Denmark).
EXAMPLE 6 This Example < poly-;-lysine and protamine sulphate (1) for binding nucleic acid to microtitre plates and (2) for carrying out assays involving hybridisation of the bound nucleic acid.
Preparation of polymer-coated plates "Falcon" PVC plates were used in both experiments. PEI, poly-L-lysine and protamine sulphate were diluted to 1 mg per ml in 5 mM sodium phosphate buffer, pH 6.8. Volumes of 100 microlitres of diluted polymer were added to each well, and the plates were incubated overnight, washed and dried as in Example 1. Duplicate rows of each of the polymer coatings were prepared. The remaining two rows of each plate were left uncoated to act as a blank control.
EXPERIMENT 1 : Binding assay In this experiment labelled and unlabelled DNA, both a cloned copy of the genome nucleic acid of Capripox virus, were allowed to compete for binding sites on the polymer-coated plates. Radioactive label label (32p) was introduced into the nucleic acid by nick-translation.
The labelled nucleic acid was separated from the unincorporated nucleotides by gel filtration, concentration by ethanol precipitation and finally diluted to a concentration of approximately 100 nanograms per ml in 5 mM sodium phosphate buffer, pH 6.8. Various dilutions of the unlabelled nucleic acid were prepared in the buffer containing the labelled DNA. The final amounts of the unlabelled DNA from 0.5 nanogram to 10 micrograms/wells are shown in Table 2. The required dilutions were calculated by taking 50 microlitres as the volume required in each well.
The nucleic acid was denatured by boiling and a 50 microlitre volume of each dilution added to the rows of two polymer-coated plates. Glutaraldehyde (6 microlitres of a 5% w/v solution) was added to the wells of one of the plates and an equal volume of sodium phosphate buffer was added to the wells of the second plate. The plates were incubated at 37 C for 30 minutes and the unbound nucleic acid removed by washing thoroughly with sodium phosphate buffer. Simple monitoring of the plates suggested that the amount of the nucleic acid bound at this stage of the experiment was the same in the presence and absence of glutaraldehyde.
Monitoring at this stage was by wide aperture geiger counter, sufficient to provide only a rough approximation of the radioactivity bound to the plates.
Both plates were treated using the conditions of hybridisation and washing described in Example 1, but no hybridisation was actually carried out. After the final wash the plates were dried and the amount of radioactivity within the individual wells measured by scintillation counting. The results are given in Table 2, in which the figures represent the mean number of counts from duplicate wells. The positive and negative symbols indicate the use or not respectively of glutaraldhyde to covalently link the DNA.
As Table 2 shows, both PEI and poly-L-lysine were highly effective in binding the DNA. The amount of unlabelled DNA which begins to compete with the labelled DNA for the polymer binding sites is 2.5 micrograms per well (56 microlitre volume) for both PEI and poly-L-lysine. The binding of DNA to both polymers was much reduced in the absence of glutaraldehyde. In contrast, protamine bound the nucleic acid poorly.
TABLE 2 Binding capacity of plates coated with polyethylene, poly-L-lysine and protamine sulphate, plus or minus glutaraldehyde Counts per minute per well Amount of unlabelled DNA per well PEI Poly-L-Lysine Protamine Blank (56 mincrolitre volume) - + - + - + - + 10 g 226 720 848 7505 672 697 62 403 5 g 229 1980 940 11360 1650 1045 155 224 2.5 g 288 20387 1833 14902 1150 2435 455 271 1 g 494 28764 2564 14889 985 1907 475 296 50 ng 985 25531 5737 15263 1677 1175 405 131 25 ng 755 26528 1222 17412 1307 2079 295 367 10 ng 1258 24536 3801 15650 2107 2762 663 362 5 ng 840 27346 4871 22382 625 2319 379 439 2.5 ng 1650 28378 4294 18277 3687 2638 1804 443 0.5 ng 1888 24429 2137 19583 2027 2595 1453 282 EXPERLMENT 2 : Hybridisation assay The results from this experiment are shown in Table 3.
Capripox virus DNA (whole genome DNA, not a cloned copy of the genome) was diluted in 5 mM sodium phosphate buffer, pH 6.8, to give final concentrations of between 200 nanograms per ml and 10 picograms per ml (10 ng/well to 0.5 pg/well respectively).
The complete range of concentrations is shown in Table 3. The DNA was denatured by boiling and 50 microlitres of each dilution added to the wells of each row. Six microlitres of 5% glutaraldehyde was used to cross-link the DNA to the treated plate, thus giving a 56 microlitre volume in each well. The experiment was continued according to the method described in Example 1.
Cloned DNA from the capripox virus genome was used as the probe and labelled with biotin-dUTP by nick-translation. Hybridisation, washing, addition of streptavadin-biotinylated horseradish peroxidase, and assay for horseradish peroxidase was carried out exactly as described in Example 1.
The results show that of the three coating agents used in this experiment PEI was the most suitable for nucleic acid hybridisation. The limit of detection of the analyte DNA in the PEI coated wells was 100 picrograms. The decrease in optical density at the 5 ng and 10 ng/well concentrations is believed due to operator error.
Although the first experiment showed that poly-L-lysine was effective in binding DNA to the plates, the second experiment shows that the DNA is not available for hybridisation to the probe. There are several possible reasons for this observation.
Either the poly-L-lysine is not a reliable agent for binding nucleic acid to plates, the nucleic acid is bound in a way that prevents hybridisation to the probe, or poly-L-lysine interferes with the hybridisation.
TABLE 3 The Figures represent the mean optical density, measured at 492 nm, of duplicate wells.
Row Well number and amount of analyte DNA per well 1 2 3 4 5 6 7 8 9 10 11 12 10 ng 5 ng 2 ng 1 ng 500 pg 200 pg 100 pg 10 pg 5 pg 2 pg 1 pg 0.5 pg A-B 0.71 1.07 1.33 1.06 0.71 0.52 0.35 0.24 0.24 0.22 0.22 0.18 C-D 0.27 0.33 0.36 0.39 0.35 0.27 0.27 0.22 0.24 0;22 0.20 0.17 E-F 0.78 0.68 0.65 0.50 0.34 0.26 0.27 0.28 0.22 0.22 0.20 0.20 G-H 0.31 0.19 0.25 0.22 0.19 0.21 0.22 0.19 0.18 0.18 0.18 0.17 Key Row A-B : PEI coated Row C-D : Poly-L-lysine coated Row E-F : Protamine sulphate coated Row G-H : Uncoted 'blank' wells Using protamine sulphate to coat the plates, the limit of detection of the analyte DNA was 500 picograms. Thus, it was less sensitive than PEI. However, it is possible that if relatively large amounts of a protamine salt are bound to the plate, it could be an alternative to PEI and accordingly this specification covers any such parallel aspect as part of the invention herein.
The following claims define some important aspects of the invention, but do not purport to include every conceivable aspect for which protection might be sought in subsequent continuing and foreign patent applications, and should not be construed as detracting from the generality of the inventive concepts hereinbefore described.

Claims (8)

1. A rigid plastics support having bonded thereto a branched polyethylenimine having (1) primary amino or cross-linkable secondary amino and (2) protonated amino groups.
2. A support according to Claim 1 in the form of a welled plastics plate having bonded to wells thereof a branched polyethylenimine having (1) primary amino or cross-linkable secondary amino and (2) protonated amino groups.
3. A support according to Claim 1 or 2 wherein the polymer is polyethylenimine is substantially as hereinbefore described.
4. A support according to Claim 1, 2 or 3 of polyvinyl chloride or polystyrene.
5. A method of immobilising a polynucleotide on a rigid plastics support which comprises incubating a support according to Claim 1, 2, 3 or 4 with the polynucleotide and with a cross-linking agent effective to link amino groups of the polyethylenimine to reactive groups on the polynucleotide.
6. A method according to Claim 5 wherein the polynucleotide is single-stranded.
7. A method of assay of a polynucleotide in an analyte, which comprises: (1) if the polynucleotide is not already in a single-stranded form, free of secondary structure or duplex which would interfere with hybridisation, denaturing it to remove said secondary structure or duplex, (2) immobilising the polynucleotide on a plastics support by a method according to Claim 5, (3) probing the immobilised polynucleotide with a labelled complementary polynucleotide under hybridisation conditions, and (4) detecting the presence or amount of label bound to the support.
8. A method according to Claim 7 wherein the polynucleotide is immobilised in wells of a welled plastics plate.
GB08627703A 1986-11-20 1986-11-20 Immobilisation of polynucleotides Withdrawn GB2197720A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08627703A GB2197720A (en) 1986-11-20 1986-11-20 Immobilisation of polynucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08627703A GB2197720A (en) 1986-11-20 1986-11-20 Immobilisation of polynucleotides

Publications (2)

Publication Number Publication Date
GB8627703D0 GB8627703D0 (en) 1986-12-17
GB2197720A true GB2197720A (en) 1988-05-25

Family

ID=10607617

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08627703A Withdrawn GB2197720A (en) 1986-11-20 1986-11-20 Immobilisation of polynucleotides

Country Status (1)

Country Link
GB (1) GB2197720A (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312135A2 (en) * 1987-09-29 1989-04-19 Findley Adhesives Inc. Polymer coated solid matrices and use in immunoassays
EP0435470A1 (en) * 1989-11-30 1991-07-03 Ortho Diagnostic Systems Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
EP0455905A2 (en) * 1990-05-11 1991-11-13 Microprobe Corporation Solid supports for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
EP0487104A1 (en) * 1990-11-22 1992-05-27 Sumitomo Electric Industries, Ltd Method of immobilizing single-stranded DNA on carrier at terminal
GB2271850A (en) * 1990-03-30 1994-04-27 Astra Ab Non-radioactive hybridisation assay for pathogens
EP0647719A1 (en) * 1992-03-19 1995-04-12 Kabushiki Kaisha Nippon Gene Solid-phase anchor carrying nucleic acid and method of adjusting the same
EP0675965A1 (en) * 1992-01-29 1995-10-11 Hitachi Chemical Co., Ltd. Polynucleotide immobilized support
WO1998030905A1 (en) * 1997-01-14 1998-07-16 Hospal Industrie Means for the biological purification of a biological fluid
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
WO1999005308A2 (en) * 1997-07-22 1999-02-04 Rapigene, Inc. Apparatus and methods for arraying solution onto a solid support
WO1999004896A1 (en) * 1997-07-22 1999-02-04 Rapigene, Inc. Polyethylenimine-based biomolecule arrays
WO1999034214A1 (en) * 1997-12-31 1999-07-08 Qiagen Genomics, Inc Solid-phase tips and uses relating thereto
WO2001044503A1 (en) * 1999-12-17 2001-06-21 Centre National De La Recherche Scientifique Biochips, preparation and uses
WO2001062963A2 (en) * 2000-02-28 2001-08-30 Variom Biotechnology Ag Method for immobilizing nucleic acids
US7008788B2 (en) * 2001-07-30 2006-03-07 Agilent Technologies, Inc. Containers for supports comprising biopolymers
US7125674B2 (en) * 1993-10-28 2006-10-24 Ut-Battelle, Llc Microfabricated flowthrough porous apparatus for discrete detection binding reactions
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US7807198B2 (en) 2000-12-19 2010-10-05 California Institute Of Technology Compositions containing inclusion complexes
US7811751B2 (en) 1988-05-03 2010-10-12 Oxford Gene Technology Limited Analysing polynucleotide sequences
US7888494B2 (en) 1988-05-03 2011-02-15 Oxford Gene Therapy Limited Analysing polynucleotide sequences
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8357377B2 (en) 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097878A2 (en) * 1982-06-28 1984-01-11 Siemens Aktiengesellschaft Control device for heating and ventilating arrangements in motor vehicles
EP0221308A1 (en) * 1985-09-30 1987-05-13 Miles Inc. Immobilization of nucleic acids on derivatized nylon supports

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097878A2 (en) * 1982-06-28 1984-01-11 Siemens Aktiengesellschaft Control device for heating and ventilating arrangements in motor vehicles
EP0221308A1 (en) * 1985-09-30 1987-05-13 Miles Inc. Immobilization of nucleic acids on derivatized nylon supports

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS ACTRA (1973) P41-52 VOL 308(1) *
WO 83/02954 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312135A3 (en) * 1987-09-29 1990-04-04 Findley Adhesives Inc. Polymer coated solid matrices and use in immunoassays
EP0312135A2 (en) * 1987-09-29 1989-04-19 Findley Adhesives Inc. Polymer coated solid matrices and use in immunoassays
US7811751B2 (en) 1988-05-03 2010-10-12 Oxford Gene Technology Limited Analysing polynucleotide sequences
US7888494B2 (en) 1988-05-03 2011-02-15 Oxford Gene Therapy Limited Analysing polynucleotide sequences
EP0435470A1 (en) * 1989-11-30 1991-07-03 Ortho Diagnostic Systems Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
US5215882A (en) * 1989-11-30 1993-06-01 Ortho Diagnostic Systems, Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
GB2271850A (en) * 1990-03-30 1994-04-27 Astra Ab Non-radioactive hybridisation assay for pathogens
GB2271850B (en) * 1990-03-30 1994-09-07 Astra Ab Non-radioactive hybridisation assay for pathogens
EP0455905A2 (en) * 1990-05-11 1991-11-13 Microprobe Corporation Solid supports for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
EP0455905A3 (en) * 1990-05-11 1992-10-07 Microprobe Corporation Solid supports for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
EP0487104A1 (en) * 1990-11-22 1992-05-27 Sumitomo Electric Industries, Ltd Method of immobilizing single-stranded DNA on carrier at terminal
EP0675965A1 (en) * 1992-01-29 1995-10-11 Hitachi Chemical Co., Ltd. Polynucleotide immobilized support
EP0675965A4 (en) * 1992-01-29 1999-01-20 Hitachi Chemical Co Ltd Polynucleotide immobilized support.
EP0647719A4 (en) * 1992-03-19 1997-08-20 Nippon Gene Kk Solid-phase anchor carrying nucleic acid and method of adjusting the same.
EP0647719A1 (en) * 1992-03-19 1995-04-12 Kabushiki Kaisha Nippon Gene Solid-phase anchor carrying nucleic acid and method of adjusting the same
US7125674B2 (en) * 1993-10-28 2006-10-24 Ut-Battelle, Llc Microfabricated flowthrough porous apparatus for discrete detection binding reactions
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6260715B1 (en) * 1997-01-14 2001-07-17 Hospal Industrie Means for the biological purification of a biological fluid
WO1998030905A1 (en) * 1997-01-14 1998-07-16 Hospal Industrie Means for the biological purification of a biological fluid
FR2758394A1 (en) * 1997-01-14 1998-07-17 Hospal Ind MEANS FOR THE SPECIFIC BIO-CLEANING OF A BIOLOGICAL FLUID
AU735546B2 (en) * 1997-07-22 2001-07-12 Qiagen Genomics, Inc. Polyethylenimine-based biomolecule arrays
WO1999004896A1 (en) * 1997-07-22 1999-02-04 Rapigene, Inc. Polyethylenimine-based biomolecule arrays
US6150103A (en) * 1997-07-22 2000-11-21 Qiagen Genomics, Inc. Polyethylenimine-based biomolecule arrays
WO1999005308A2 (en) * 1997-07-22 1999-02-04 Rapigene, Inc. Apparatus and methods for arraying solution onto a solid support
US6365349B1 (en) 1997-07-22 2002-04-02 Qiagen Genomics, Inc. Apparatus and methods for arraying solution onto a solid support
WO1999005308A3 (en) * 1997-07-22 1999-05-27 Rapigene Inc Apparatus and methods for arraying solution onto a solid support
WO1999034214A1 (en) * 1997-12-31 1999-07-08 Qiagen Genomics, Inc Solid-phase tips and uses relating thereto
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
WO2001044503A1 (en) * 1999-12-17 2001-06-21 Centre National De La Recherche Scientifique Biochips, preparation and uses
FR2802550A1 (en) * 1999-12-17 2001-06-22 Centre Nat Rech Scient BIOCUCES, PREPARATION AND USES
WO2001062963A3 (en) * 2000-02-28 2002-04-25 Variom Biotechnology Ag Method for immobilizing nucleic acids
WO2001062963A2 (en) * 2000-02-28 2001-08-30 Variom Biotechnology Ag Method for immobilizing nucleic acids
US8277846B2 (en) 2000-12-19 2012-10-02 California Institute Of Technology Complexing agents for compositions containing inclusion complexes
US7968123B2 (en) 2000-12-19 2011-06-28 California Institute Of Technology Complexing agents for compositions containing inclusion complexes
US8092833B2 (en) 2000-12-19 2012-01-10 California Institute Of Technology Compositions containing inclusion complexes
US7807198B2 (en) 2000-12-19 2010-10-05 California Institute Of Technology Compositions containing inclusion complexes
US7008788B2 (en) * 2001-07-30 2006-03-07 Agilent Technologies, Inc. Containers for supports comprising biopolymers
US8404662B2 (en) 2002-09-06 2013-03-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8518388B2 (en) 2002-09-06 2013-08-27 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8314230B2 (en) 2002-09-06 2012-11-20 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9550860B2 (en) 2002-09-06 2017-01-24 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8389499B2 (en) 2002-09-06 2013-03-05 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8399431B2 (en) 2002-09-06 2013-03-19 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8475781B2 (en) 2002-09-06 2013-07-02 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8680202B2 (en) 2002-09-06 2014-03-25 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580244B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580242B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580243B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8603454B2 (en) 2002-09-06 2013-12-10 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8609081B2 (en) 2002-09-06 2013-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8357377B2 (en) 2002-10-09 2013-01-22 Suzie Hwang Pun Cyclodextrin-based materials, compositions and uses related thereto
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US9610360B2 (en) 2007-01-24 2017-04-04 Ceruliean Pharma Inc. Polymer drug conjugates with tether groups for controlled drug delivery
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Also Published As

Publication number Publication date
GB8627703D0 (en) 1986-12-17

Similar Documents

Publication Publication Date Title
GB2197720A (en) Immobilisation of polynucleotides
CA1288709C (en) Immobilization of nucleic acids on derivatized nylon supports
US4806631A (en) Immobilization of nucleic acids on solvolyzed nylon supports
US5374524A (en) Solution sandwich hybridization, capture and detection of amplified nucleic acids
EP0455905B1 (en) Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US4994373A (en) Method and structures employing chemically-labelled polynucleotide probes
US20030148362A1 (en) Diagnostic microarray and method of use thereof
AU599013B2 (en) Solution-phase dual hybridization assay for detecting polynucleotide sequences
US6268141B1 (en) Immobilization of unmodified biopolymers to acyl fluoride activated substrates
EP0439222B1 (en) Water-insoluble reagent, nucleic acid probe, test kit and diagnostic and purification methods
US6037124A (en) Carboxylated polyvinylidene fluoride solid supports for the immobilization of biomolecules and methods of use thereof
EP0436547B1 (en) Process for rapid nucleic acid detection
US5053326A (en) Hybridization method and probe
JPH06506768A (en) Protein-nucleic acid probes and immunoassays using them
US20110086771A1 (en) Biochip
Suzuki et al. Efficient immobilization of proteins by modification of plate surface with polystyrene derivatives
US6180769B1 (en) Method for linking negatively charged macrobiomolecules to plastics, resulting linked compositions and microtitre plates incorporating same
US6306657B1 (en) Polynucleotide probe and kit for amplifying signal detection in hybridization assays
EP0406280A1 (en) Method for amplifying and detecting nucleic acid in a test liquid
PT677589E (en) METHODS TEST ELEMENT AND TEST CASE FOR SEMI-QUANTITATIVE NUCLEIC ACID DETECTION
EP0401313B1 (en) Macromolecular conjugate
JPH0657160B2 (en) Hybridization assay

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)